All In Biotech

Drug Trial Radar · NCT02616302

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

Feb 20, 2023

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of GERD include pain in the stomach or throat, difficulty eating, and throwing up. Symptomatic nonerosive GERD is a condition where people have the symptoms of GERD but the esophagus has not been damaged. People of all ages can have GERD. The causes of GERD in children are similar to those in adults and teenagers. Dexlansoprazole is a medicine that has been shown to help relieve the symptoms of GERD in adults and teenagers. This study aims to find out if dexlansoprazole doses given to children with symptomatic nonerosive GERD, based on their body weight, helps them feel better.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • DexlansoprazoleDrug

    Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Days Without Hurting or Burning in the Stomach, Chest or Throat Over the 12 Weeks of TreatmentTime frame: Up to 12 weeks

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Childrens Center for Digestive Health Care, LLC

    Mobile, Alabama

  • University of Utah/ Primary Childrens Hospital

    San Francisco, California

  • GI For Kids

    Atlanta, Georgia

  • Childrens Hospital of The Kings Daughters

    Jackson, Mississippi

  • The University of Chicago

    Cleveland, Ohio

  • National Research Centers

    Norfolk, Virginia

  • Women and Children's Health Research Institute

    Edmonton, Alberta, Canada

  • London Health Sciences Centre Children's Hospital

    London, Ontario, Canada

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Fundacion Valle del Lili

    Cali, Colombia

  • Centro Medico Imbanaco de Cali S.A

    Cali, Colombia

  • El Cielo Medical Center

    Puebla City, Mexico

  • SMIQ, S. DE R.L. DE C.V. Queretaro

    Querétaro, Mexico

  • Boca Clinical Trials Mexico S.C.

    Querétaro, Putumayo, Mexico

  • Clinical Research Institute S.C.

    Tlalnepantla, State of Mexico, Mexico

  • In Vivo Osrodek Badan Klinicznych

    Bydgoszcz, Poland

  • Instytut "Pomnik - Centrum Zdrowia Dziecka", Oddzial Gastroenterologii, Hepatologii, Zaburzen odzywiania i Pediatrii

    Warsaw, Poland

  • Gabinet Lekarski Bartosz Korczowski

    Rzeszów, PL, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.